Klin Farmakol Farm. 2015;29(2):65-68
Malignant melanoma with BRAF mutation and its treatment options
- Dermatovenerologická ambulance, Praha
Malignant melanoma is a tumour with a steadily increasing incidence. There are already more than 20 newly reported melanomas per
100,000 population a year. In the Czech Republic, the incidence of melanoma has increased four-fold in the last 30 years. It accounts for
about 5% of all malignant skin cancers and is one of the most malignant tumours there is. It can occur on the skin (90%), the mucosae
(1%; in the Asian population 5–8%), or in the eye (3–5%). The principal therapeutic option is surgical treatment; the previously used
actinotherapy and systemic chemotherapy (in metastatic disease) have nowadays been replaced by biological therapy.
Keywords: malignant melanoma, BRAF mutation, BRAF inhibitors, immunotherapy, BRAF kinase
Published: July 1, 2015 Show citation
References
- Krajsová I. Melanom, vyd. Maxdorf, 2006.
- www.mojemedicina.cz.
- Paul B, Chapman, et al. Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with *BRAFV600E*-mutated melanoma.
- SPC přípravku Zelboraf.
- SPC přípravku Tafinlar.